Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRory McCullochGloucestershire Hospitals NHS Foundation TrustVVVaishak VidyadharUniversity College London Hospitals NHS Foundation TrustGPGavin PrestonAberdeen Royal Infirmary

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows treatment efficacy and poor outcomes in TP53 aberrant mantle cell lymphoma, suggesting urgent need for novel approaches.

Key Points

  • To assess outcomes in patients with TP53 aberrant mantle cell lymphoma receiving first-line systemic therapy.
  • Multicenter retrospective analysis of anonymised data from 120 patients with TP53 aberrant MCL.
  • Data collected on baseline characteristics, response to treatment, and overall survival.
  • Overall survival defined as median time from start of first-line therapy.
  • Overall response rate to first-line therapy was 68%, with a complete response rate of 45%.
  • Median treatment failure free survival was 13.9 months, with estimated median overall survival of 29.8 months.
  • LDH ratio >1.5 was predictive of overall survival with hazard ratio 2.3.

Cite This Study

McCulloch et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d470https://doi.org/10.1182/blood-2025-1827
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project2025
  2. 2Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025
  3. 3Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  4. 4Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis2025
  5. 5Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations